Brief: Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

Yuhan

11/03/2019 11:20

March 11 (Reuters) - Yuhan Corp  000100.KS :
    * YUHAN CORP AND SORRENTO THERAPEUTICS ANNOUNCE COMPLETION
OF
PHASE 1 CLINICAL STUDY OF ANTI-PD-L1 ANTIBODY IMC-001

Source text for Eikon:  ID:nGNX7RCl2c 
Further company coverage:  000100.KS 

 ((Reuters.Briefs@thomsonreuters.com;))